Drug Discovery

#4BIO Capital #Drug development #Drug discovery #Investment #Life sciences

New podcast: Investment trends for drug discovery and development

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Owen Smith, Partner at… Read More

#News

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

What will the future bring in cell and gene therapies?

Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and… Read More

#News

#AI / data analytics / healthtech / informatics #Business #Digital solutions #Digital workflow #Drug development #Drug discovery #EMA #FDA #Marketing #Pharmaceuticals #Regulatory

New podcast: How to streamline regulatory approval

This is the latest episode of the free DDW narrated podcast, titled “How to streamline regulatory approval”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Quicker time to regulatory submission through improved data management and The… Read More

#News #Regulatory

Flow cytometry
#Drug discovery #Flow Cytometry #Lab technology #Tech Focus

Flow cytometry: Shining a light on new therapeutics

Diana Spencer explores the latest innovations in flow cytometry technology and the potential for the technique in the future of drug discovery. Flow cytometry is a technique used to rapidly analyse single cells to characterise their physical, chemical and biological properties. The technology was invented in 1968 by Wolfgang Göhde… Read More

#Exclusive Content

Concussion brain scan
#Concussion #Drug development #Drug therapy #Oxeia Biopharmaceuticals

New podcast: The unmet critical need for concussion drug therapies

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with CEO of… Read More

#News

Dementia
#Alzheimer's #Drug development #Eli Lilly #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE) #Regulatory

UK’s NICE rejects second disease-modifying therapy for Alzheimer’s 

UK regulator the National Institute for Health and Care Excellence (NICE) has ruled against the use of a second monoclonal antibody for Alzheimer’s disease, just two months after rejecting Eisai’s lecanemab (Leqembi).  NICE concluded that Eli Lilly’s donanemab (Kisunla) only provides a “small benefit”… Read More

#News

#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy #Webinar

Register now for DDW’s Cell & Gene Therapy Showcase

Join the DDW Cell & Gene Therapy Showcase, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio. In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery & development sector as well as highlighting challenges… Read More

#News

#Biotechnology #Clinical trials #Drug development #Fibrotic disease

Calluna Pharma advances lead candidate for fibrotic diseases 

Biotechnology company Calluna Pharma has completed a Phase I clinical study for its lead product candidate targeting inflammatory and fibrotic diseases.  The company’s lead candidate, CAL101, was shown to have a favorable safety, pharmacokinetic (PK) and immunogenicity profile in the Phase I study.  CAL101 is… Read More

#News

Cancer research in laboratory
#Breast cancer #Drug approvals #Drug discovery #Oncology

Early breast cancer drug Kisqali gets EU recommendation 

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation for Novartis’ Kisqali (ribociclib).  The positive opinion relates to the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC),… Read More

#Cancer Research #News

Diversity
#Clinical trials #Diversity #Drug development #Drug discovery #FDA #Inclusivity

Opinion: Are FDA plans enough to boost inclusivity within clinical trials?

DDW Editor Reece Armstrong examines whether recent FDA plans to boost diversity within clinical trials are enough to tackle the scale of the problem. In June this year, the US Food and Drug Administration (FDA) issued draft guidance designed to help boost the engagement of underrepresented communities within clinical… Read More

#Exclusive Content

#Biopharma #Drug development #Drug discovery #Oncology #Partnership

Sanofi and Orano invest in potential of radioligand cancer medicines 

Sanofi and Orano Med have entered into an agreement with the aim of accelerating the development of radioligand medicines.  Building on the radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand.  The new entity… Read More

#News

Woman with painful shoulder
#Clinical trials #Drug development #Drug discovery #Phase I trial

Novel pain relief drug enters Phase I trials 

The first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist, which it is hoped will treat chronic pain without the potential for abuse.   The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and… Read More

#News

Neuroscience innovation
#Drug development #Drug discovery #Neuroscience #Webinar

Watch DDW’s Neuroscience Showcase On Demand

In this free online event at 3pm BST on 24 October, hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector.  The showcase includes a panel discussion looking at… Read More

#News

#Clinical trial design #Clinical trials #Drug development #Drug discovery

Is disclosure non-compliance harming drug development?

Ali Pashazadeh, Founder and CEO of Treehill Partners, explores how clinical trial disclosure non-compliance is placing major pressures on clinical development, biopharma investment, and patient access to life saving therapies. Clinical trial disclosure non-compliance is rarely discussed and often ignored as a problem in the drug development sector. It is,… Read More

#Exclusive Content

#Biotherapeutics #Drug development #Tech transfer #Thermo Fisher Scientific

New listicle: Four tips for successful tech transfer

Tech transfer is all about transferring technology, knowledge, and expertise from one phase of development to another, or from one facility to another, to ensure the successful replication and scaling up of biotherapeutic products. This involves several key activities such as knowledge and process transfer, process standardisation, quality and compliance,… Read More

#News

Laboratory freezer
#Lab equipment #Lab technology #Laboratory #Sample preparation

Smart Note: Cut energy costs in the lab by up to 37%

Do you know the most efficient way to cut energy consumption in the lab while still preserving precious biological samples? Download the new Smart Note from Thermo Fisher Scientific entitled ‘Reduce costs, while continuing to safeguard samples, by raising the setpoint for ULT freezers from –80°C to –70°C‘. Learn… Read More

#News